Moreover, 5-HT3 antagonism has been proposed as a therapeutic approach for a number of indications such as depression, emesis, irritable bowel syndrome (IBS), schizophrenia, anxiety, cognitive deficit, pruritis, inflammation, and pain (Thompson and Lummis 2007). This evidence concerns the gene HTR3A and irritable bowel syndrome.